Avapritinib was approved by the FDA for any line of treatment for GIST with PDGFRA D842V and other exon 18 mutations, based on results from the phase 1 NAVIGATOR study, which showed an RR of 88% in patients with PDGFRA D842V [14]. Here, PDGFRA is linked to gastrointestinal stromal tumor.